Intensity Therapeutics (NASDAQ:INTS) reported quarterly losses of $(0.96) per share which beat the analyst consensus estimate of $(1.11) by 13.51 percent. This is a 82.55 percent increase over losses of $(5.50) per share from the same period last year.